Views

CrossRef citations to date

Altmetric

Overactive Bladder Syndrome Treatment With Ospemiphene

Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?

Michele Carlo SchiaviDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy; Correspondence[email protected]

Valentina SciugaDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Andrea GianniniDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Flaminia VenaDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Ottavia D’oriaDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Giovanni PrataDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Chiara Di TucciDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Delia SavoneDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Natalia AleksaDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Carmela CaponeDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Daniele Di MascioDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Maria Letizia MeggioriniDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Marco MontiDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Marzio Angelo ZulloDepartment of Surgery-Week Surgery, Campus Biomedico, University of Rome, Rome, Italy

Ludovico MuziiDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

Pierluigi Benedetti PaniciDepartment of Gynecological and Obstetric Sciences, and Urological Sciences, Umberto I Hospital, University of Rome “Sapienza”, Rome, Italy;

show all

Abstract

The aim of this study was to assess the effectiveness of ospemifene in the improvement of sexual function in postmenopausal women with vulvovaginal atrophy (VVA) affected by overactive bladder syndrome (OAB) or urge urinary incontinence (UUI). One hundred five postmenopausal patients with VVA affected by OAB and/or UUI were enrolled for the study. All patients received ospemifene 60 mg for 12 weeks. Clinical examination, 3-d voiding diary and the vaginal health index (VHI) were performed at baseline and at 12 weeks. Patients completed the OAB-Q SF, FSFI, FSDS, and SF-36 questionnaires. The patient’s satisfaction was also calculated. After 12 weeks, the reduction of urinary symptoms was observed. The OAB-Q symptoms, OAB-Q (HRQL) score were (55.34 ± 13.54 vs. 23.22 ± 9.76; p < .0001) and (22.45 ± 9.78 vs. 70.56 ± 15.49; p < .0001), before and after treatment. SF-36 questionnaire showed a significant improvement (p < .0001). VHI score increased and the women who regularly practice sexual activity increased after treatment. The total FSFI score increased significantly and the FSDS score changed after 12 weeks (p < .0001). The PGI-I after 12 weeks showed a total success rate of 90.5%. Ospemifene is an effective potential therapy for postmenopausal women with VVA affected by OAB or UUI improving sexual function and quality of life.

Chinese abstract

奥斯米芬治疗更年期外阴阴道萎缩的膀胱过度活跃综合征：性的改善？

摘要

本研究旨在评估奥司米芬改善因膀胱过度活跃综合征（OAB）或急迫性尿失禁（UUI）引起外阴阴道萎缩（VVA）绝经后妇女性功能的效果。105例绝经后因OVA/UUI引起VVA的绝经后患者纳入本研究。所有患者均口服奥司米芬60mg, 连续12周。在开始和12周进行临床检查、3-D排尿日记和阴道健康指数（VHI）。患者完成OAB-Q SF、FSFI、FSDS和SF-36问卷。患者满意度也计算在内。12周后, 观察泌尿症状减少。治疗前后OAB-Q症状、OAB-Q（HRQL）评分分别为（55.34 ± 13.54 vs. 23.22 ± 9.76; p<.0001）、(22.45 ± 9.78 vs. 70.56 ± 15.49; p<.0001)。治疗后VHI评分增加, 定期性活动增加。12周后总FSFI评分明显升高, FSDS评分改变（p＜.0001）。12周后PGI-I总有效率为90.5%。奥司米芬是OAB或UUI引起VVA的绝经后妇女改善性功能和生活质量的有效潜在治疗方法。

关键词: 外阴阴道萎缩；膀胱过度活跃综合征；奥斯米芬；性功能；生活质量

Keywords:

Disclosure statement

The authors report no conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?

Information for

Open access

Opportunities

Help and information

Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?

Abstract

Chinese abstract

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature